4.5 Review

Ectopic calcification in diabetic vascular disease

Journal

EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 18, Issue 5, Pages 595-609

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2014.894021

Keywords

atherosclerosis; cardiovascular risk; inflammation; remodeling

Funding

  1. Bristol Myers Squibb
  2. Merck Sharpe Dohme
  3. Novartis Pharmaceutical Co.
  4. Novo Nordisk
  5. Boehringher

Ask authors/readers for more resources

Introduction: Cardiovascular diseases represent over one-half of all deaths in both type 1 and type 2 diabetes mellitus. In diabetic patients, vascular calcifications are more frequently observed than in people without diabetes. In particular, elevated degrees of coronary artery and valvular calcifications are reported in populations with diabetes. Areas covered: We will present and discuss findings from clinical and basic science studies that investigate the pathophysiological processes leading to exaggerated arterial/valve calcification in diabetic patients. We will also illustrate the likely effects of the current therapies on vascular calcification progression in diabetic patients. A special focus will be dedicated to the contribution of resident/circulating calcifying cells to the calcific processes observed under diabetic conditions. Expert opinion: Interest in the topic of ectopic calcification in diabetic vascular disease is expanding and more knowledge is adding on its mechanisms and consequences. Importantly, new therapeutic targets are emerging, implying possible future chances to modulate vascular calcification for cardiovascular protection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available